ORIC Pharmaceuticals Inc. (ORIC) stock soared 7.21% in Tuesday's trading session, following the company's announcement of focused registrational clinical development plans for its lead programs, ORIC-944 and ORIC-114, and an extension of its projected cash runway into 2027.
In the press release, ORIC outlined its plans to prioritize the development of ORIC-944, a PRC2 inhibitor for metastatic castration-resistant prostate cancer (mCRPC), and ORIC-114, an EGFR/HER2 inhibitor for non-small cell lung cancer (NSCLC). Specifically, the company expects to initiate the first Phase 3 trial for ORIC-944 in mCRPC in the first half of 2026, and plans to initiate Phase 3 trial(s) for ORIC-114 in first-line NSCLC in 2026, focusing on EGFR exon 20, HER2 exon 20, and atypical EGFR mutations.
Additionally, ORIC announced accelerated and augmented corporate milestones, including combination dose escalation data for ORIC-944 in mCRPC expected in the first and second halves of 2025, and comprehensive NSCLC data for ORIC-114 expected in the second half of 2025, which includes first-line EGFR exon 20. The company's projected cash runway has been extended into 2027 under the refined operating plan.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。